Regeneron Pharmaceuticals, Inc. Reports First Quarter Results
TARRYTOWN, N.Y. -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has revealed its financial and operational performance for the first quarter of 2025.
Financial Overview
The company announced significant revenues of $3.0 billion for the first quarter of 2025. The GAAP diluted earnings per share (EPS) stood at $7.27, while the non-GAAP diluted EPS reached $8.22. These figures mark Regeneron's ongoing strength in the biotechnology sector.
Key Business Highlights
During this quarter, Regeneron's flagship product, Dupixent, recorded impressive global net sales of approximately $3.67 billion, a 19% increase from the same quarter last year. Meanwhile, EYLEA HD's U.S. sales surged by 54% year-over-year, totaling $307 million.
Additional achievements included the FDA approval of Dupixent for chronic spontaneous urticaria (CSU) and chronic obstructive pulmonary disease (COPD) in Japan. The ongoing innovation is reflected in EYLEA HD's supplemental Biologics License Application (sBLA) acceptance for priority review. This submission focuses on treatment for retinal vein occlusion (RVO) and monthly dosing options.
Expansions and Infrastructure Investments
Regeneron is not just focusing on existing products but also on expanding its future capabilities. The company announced plans for over $7 billion in investments to enhance its infrastructure and manufacturing capacities in North Carolina and New York. This strategic move will support Regeneron’s ambitious pipeline and solidify its position in the biotechnology landscape.
Regulatory and Pipeline Updates
The company is continuously advancing its pipeline, with approximately 45 product candidates in clinical development. Notable mentions include Lynozyfic™ (linvoseltamab), recently approved in the EU for relapsed or refractory multiple myeloma. Regeneron’s collaboration with Sanofi has yielded robust results, particularly reflecting in Dupixent's sales performance.
Furthermore, Regeneron has made strides in oncology, evident by submissions for Libtayo® in adjuvant cutaneous squamous cell carcinoma (CSCC) and the progression of their bispecific antibody programs.
Future Financial Guidance
Looking ahead, Regeneron outlined its financial guidance for 2025, projecting GAAP Research and Development expenses between $5.560 billion and $5.795 billion. The anticipated non-GAAP R&D expenses are expected to be between $5.000 billion and $5.200 billion. Regulatory expectations suggest a robust growth trajectory with a gross margin of 84% to 85%, highlighting the company’s efficiency in operations.
Moreover, Regeneron continues to prioritize shareholder returns, as demonstrated by its new share repurchase program, which allows for repurchases of up to $3 billion in common stock, enhancing its commitment to shareholder value.
Contact and Additional Information
For further insights into Regeneron's performance and updates, individuals are encouraged to explore the company's website or access financial statements provided in their quarterly reporting.
Frequently Asked Questions
What were Regeneron's revenues for Q1 2025?
Regeneron reported revenues of $3.0 billion for the first quarter of 2025.
How did Dupixent perform compared to last year?
Dupixent's global net sales increased by 19%, totaling $3.67 billion compared to Q1 2024.
What infrastructure investments is Regeneron planning?
Regeneron plans to invest over $7 billion in its infrastructure and manufacturing capabilities in New York and North Carolina.
What pipeline developments were highlighted?
Regeneron has approximately 45 product candidates in development, including approvals for Dupixent and Lynozyfic™.
What is the projected financial guidance for 2025?
The company expects GAAP R&D expenses to range between $5.560 billion and $5.795 billion.
